the warning. but it s very difficult. pharmaceutical companies like glaxosmithkline have tens of thousands of representatives who have basically insisted that the drug is safe, and so their market share has fallen but the drug is still used by many hundreds of thousands of people. this does raise a lot of questions, as you ve talked about, about how drugs are approved, how we monitor the safety of drugs. you remember vioxx which was an anti-inflammatory i believe used for arthritis. very similar issue. we obviously want drugs out on the market to save lives but how do we refine and streamline the fda process if that is indeed the case? i think we divide the new approval process into one division and we get a separate division of the fda, the safety officials, the authority to remove drugs or put warning lanes on. we create a separation of powers that allows each of those roles in the fda to be able to proceed with independence. if we do that, i think we can